Results for &quot;&quot;Lipoproteins, IDL&quot;&quot;[mesh_terms]

Atherogenic lipoproteins in end-stage renal disease.

T Shoji, T Tabata, M Inaba, Y Nishizawa, E Ishimura

American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;38(4 Suppl 1):S30-3

Cardiac telerehabilitation with long-term follow-up reduces GlycA and improves lipoprotein particle profile: A randomised controlled trial.

Ernesto Dalli-Peydró, Rafael Gisbert-Criado, Nuria Amigó, Nuria Sanz-Sevilla, Juan Cosín-Sales

International journal of cardiology 2022;369():60-64

Insights into the pivotal role of statins and its nanoformulations in hyperlipidemia.

Aayush Sehgal, Simona Bungau, Ishrat Zahoor, Yosif Almoshari, Ahmad Salawi, Sukhbir Singh, Neelam Sharma, Tapan Behl, Neha Kanojia, Syam Mohan, Lotfi Aleya

Environmental science and pollution research international 2022;29(51):76514-76531

Atherogenic lipoprotein phenotype and diet-gene interactions.

R M Krauss

The Journal of nutrition 2001;131(2):340S-3S

Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study.

Fabrice Bonnet, Valerie Aurillac-Lavignolle, Dominique Breilh, Rodolphe Thiébaut, Evelyne Peuchant, Noëlle Bernard, Denis Lacoste, François Dabis, Jacques Beylot, Geneviève Chêne, Philippe Morlat

HIV clinical trials 2007;8(1):53-60

Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a.

Robert H J Bandsma, Berthil H Prinsen, Monique de Sain van Der Velden, Jan-Peter Rake, Theo Boer, G Peter A Smit, Dirk-Jan Reijngoud, Folkert Kuipers

Pediatric research 2008;63(6):702-7

Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.

Dick C Chan, Gerald F Watts, P Hugh R Barrett, Trevor A Mori, Lawrence J Beilin, Trevor G Redgrave

The Journal of clinical endocrinology and metabolism 2002;87(5):2283-9

Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.

M J Chapman, G Le Naour, D Milosavljevic, S Griglio

Atherosclerosis 2001;155(1):251-60

Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Keith C Norris, Nosratola D Vaziri

Blood purification 2013;35(1-3):31-6

Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial.

Celia Bañuls, Susana Rovira-Llopis, Rosa Falcón, Silvia Veses, Nuria Monzó, Víctor M Víctor, Milagros Rocha, Antonio Hernández-Mijares

Clinical nutrition (Edinburgh, Scotland) 2018;35(3):600-7

Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.

Sung-Joon Lee, Frank M Sacks

The American journal of cardiology 2003;92(2):121-4

Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

B Vergès, E Florentin, S Baillot-Rudoni, S Monier, J M Petit, D Rageot, P Gambert, L Duvillard

Diabetologia 2008;51(8):1382-90

A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals.

Sudeep Shrestha, Jeff S Volek, Jay Udani, Richard J Wood, Christine M Greene, Dimple Aggarwal, John H Contois, Ben Kavoussi, Maria Luz Fernandez

The Journal of nutrition 2006;136(10):2492-7

Effect of the Fat Eaten at Breakfast on Lipid Metabolism: A Crossover Trial in Women with Cardiovascular Risk.

Jessica M Delgado-Alarcón, Juan José Hernández Morante, Francisco V Aviles, María D Albaladejo-Otón, Juana M Morillas-Ruíz

Nutrients 2021;12(6):1695